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Background: Infections with respiratory viruses can activate the innate immune response - an important host
defence mechanism in the early stage of viral infection. Interferon (IFN) release, triggered by virus infection, is an
important factor in establishing an antiviral state, where IFN activation occurs prior to the onset of the adaptive
immune response.
The two ultra-low-dose combination medications, Engystol® and Gripp-Heel®, have documented efficacy for the
treatment of the respiratory infections. However, the underlying antiviral mechanisms remain elusive.
Methods: It was the goal to investigate whether Engystol® and Gripp-Heel® display antiviral activity in a
prophylactic treatment protocol (2, 24 and 48 h pre-incubation) using a plaque reduction assay and whether the
medications affect the release of type 1 IFN in virus-susceptible cell lines and human peripheral blood
mononuclear cells (PBMCs).
Results: Both medications demonstrate prophylactic effect against viral respiratory virus replication. However, when
the incubation was continued for up to 5 days, both medications exhibited a pronounced antiviral effect which
was dependent on the pre-incubation time. Moreover, in co-stimulated HeLa cells as well as in activated PBMCs
Gripp-Heel® and Engystol® demonstrated an increased type 1 IFN production.
Conclusions: Engystol® and Gripp-Heel® inhibited the replication of a variety of respiratory viruses. Additionally, we
showed that pre-incubation affects the magnitude of the inhibitory effect differently for the various tested viruses.
Both medications stimulate type 1 IFN release in different cell systems which suggests that their antiviral activity
may be mediated possibly via modulation of the antiviral type 1 IFN host response.
Introduction
Viral infections of the respiratory tract are among the
most common diseases for which patients seek medical
advise. Some causative viruses for the common cold
include influenza, parainfluenza, respiratory syncytial
virus (RSV), rhinovirus (HRV) and adenovirus. The
organism’s immune system is normally well prepared to
recognize and trigger host defence mechanisms to limit
the spread of the viral infection.
The two ultra-low-dose complex medications
(ULDCM) Engystol® and Gripp-Heel® are frequently
used for prophylactic as well as acute symptomatic
treatment of infectious diseases. In observational studies,
Engystol® showed a reliable therapeutic efficacy [1],
reduced clinical symptoms and brought on more rapid
relief [2]. A study comparing an Engystol® treatment
group with a common over-the-counter (OTC) treat-
ment demonstrated that the efficacy of the ultra-low-
dose combination medicati o nw a sn o ni n f e r i o rt ot h e
OTC treatment group [3]. However, there was a ten-
dency for more rapid symptomatic improvement in the
Engystol®-treated group. Gripp-Heel® is mainly used
symptomatically during a viral infection. An observa-
tional study showed that for the symptomatic treatment
of a mild viral infection, Gripp-Heel® is as effective as
conventional therapies consisting of antitussives and
nonsteroidal antiinflammatory drugs (NSAIDS) [4,5].
Only a limited number of studies have provided
experimental evidence of how Engystol® and Gripp-
Heel® exert their therapeutic efficacy. Nevertheless, pre-
vious in vitro experiments have demonstrated the anti-
viral activity against a broad panel of viruses. These
studies showed reductions in infectivity against a panel
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virus, adenovirus, influenza A virus, RSV, parainfluenza
virus, rhinovirus and coxsackievirus [6,7]. Other in vitro
studies have demonstrated that Engystol® exerts modula-
tory effects on the immune system in terms of phagocy-
tic activity, granulocyte function and improved humoral
response [8-13]. However, the research conducted on
this topic so far falls short on clarifying the possible
molecular mechanisms of Engystol® and Gripp-Heel® in
either the laboratory or the clinical setting.
The innate immune response is the first guardian in
defending the body against pathogens. Central to this
host antiviral response is the production of interferons
(IFNs). There are two types of IFNs: type I or ‘viral’
IFNs (IFN-a,I F N - b and IFN-ш) and type II IFN (IFN-
g). The synthesis of type I IFN is triggered by viral infec-
tion acting on IFN-regulatory factors (IRFs), while type
II IFN is induced by mitogenic or antigenic stimuli [14].
The regulation of IFN production is dependent on the
virus strain, the kind of infected host cell and type of
IFN. Multiple Toll-like receptors (TLR)-dependent
(TLR-3,-4,-7 and -9) and independent -RIG-I (cytoplas-
mic helicase RNA protein) as well as Mda5 pathways
are involved in the cell-type specific regulation of type I
IFNs. Collaboration between the pathways is required to
ensure a robust and controlled activation of antiviral
response. Induction of type I IFN is regulated at the
transcriptional level and is specifically achieved by mem-
bers of the IRF transcription factor family [15]. Type I
IFN induces various genes that encode proteins involved
in innate and adaptive antiviral immune responses.
This study aimed to investigate the antiviral activity
of Gripp-Heel® and Engystol® using a pre-treatment
("prophylactic” treatment protocol) and a continuous
("therapeutical” treatment protocol) by means of plaque
reduction assay. As a second step, we wished to establish
whether both preparations exert their antiviral activity by
stimulating the host’s IFN response. We were indeed able
to demonstrate for the first time, that both medications
can stimulate IFN production in an epithelial cell line as
well as in cells of the immune system (PBMCs).
Materials and methods
Test preparations
Gripp-Heel® (stock 24335-05.2011) and Engystol® (stock
22981-02.2001) solution were supplied as sterile
ampoules (1.1 ml H2O) from Biologische Heilmittel
Heel (Baden-Baden, Germany). Gripp-Heel® contains
Aconitum (D4), Byronia (D3), Lachesis (D11), Eupator-
ium perfoliatum (D2) and phosphorus (D4). Engystol®
contains Vincetoxicum hirundinaria (D6), Vincetoxicum
hirundinaria (D10), Vincetoxicum hirundinaria (D30),
sulphur (D4) and sulphur (D10). The test preparations
were diluted in cell culture medium before addition to
the cell culture. Final concentrations in the assays
ranged from 1:4 to 1:320.
Cell culture and viruses
Human rhinovirus B serotype 14 (HRV-14) was obtained
from the Institute for Virology (University of Jena,
Germany). Influenza A virus (FluA), Chile 1/83 (H1N1),
herpes simplex virus 1 (HSV-1, strain Thea), vesicular sto-
matitis virus (VSV, FL1), respiratory syncytial virus (RSV,
strain Long), parainfluenza type 3 (Para3) and adenovirus
type 5 (Ad5) were obtained from the Friedrich-Löffler
Institute (FLI) Tübingen and the Department of Medical
Virology and Epidemiology of Virus Diseases of the
Hygiene Institute at University of Tübingen, respectively.
For IFN assays
HeLa cells (University of Jena, Germany) were incubated
with UV-inactivated HRV-14, Hep-2 cells (CCL-23,
ATCC) with UV-inactivated HSV-1 and Madin-Darby
canine kidney cells (MDCK) with UV-inactivated FluA.
For cultivation of viruses
Hep-2 and HeLa cells were cultivated in MEM with
Hanks’ buffered saline solution containing 2% fetal calf
serum (FCS, PAA, Pasching, Austria), 25 mM MgCl2,2
mM L-glutamine, 100 U/ml penicillin and 0.1 mg/ml
streptomycin). Cells were incubated in serum-free MEM
containing 1 μg/ml trypsine, 2 mM L-glutamine, 100 U/ml
penicillin and 0.1 mg/ml streptomycin.
Determination of virus titre
The respective cells were incubated in 12-or 24 well tis-
sue culture dishes with serially diluted serum-free virus
stock solutions for 1 h at 34°C as described elsewhere [6].
Isolation of PBMCs
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from healthy donors (Wiener Rotes Kreuz, Wien,
Austria). Healthy donors were identified by diagnostic
parameters (negative haemogram, infection serology).
The blood samples were treated with heparin (Sigma)
and subjected to Ficoll-Hypaque (1,077 g/l PAA) density
gradient centrifugation (30 min. 2100 rpm). The PBMCs
were isolated from the interphase, subsequently washed
twice with medium (RPMI 1640, 10% FCS) and counted
using the trypan blue exclusion test.
The cells were incubated for 2 to 6 days with the test
preparations before being tested for IFN release (96-well
round bottom microtiter plates, Greiner, Bio-one,
Kremsmünster, Austria, 2 × 10
5 cells/well, RPMI 1640,
10% FCS). In an alternative approach, cells were co-sti-
mulated with HSV-UV to induce IFN synthesis.
Virus titration for costimulation experiments
To induce IFN release in PBMCs and virus-susceptible
cell lines, virus suspensions of inactivated HSV-1, HRV-
14 and FluA were employed.
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8 PFU/ml) of the
respective viruses were produced and inactivated with
an UV-GS linker. The virus titre inducing 20-30% IFN
synthesis (calculated with an IFN-a standard) was deter-
mined in serial dilutions and kinetic experiments.
Plaque formation assays and virus-specific ELISA
The antiviral activity of Gripp-Heel® against influenza,
Para3, RSV, HRV-14, HSV-1 and Ad5 was determined
by means of a plaque formation assay or cytopathogenic
effect (CPE), respectively as described elsewhere [6]. For
Ad5 a virus specific ELISA was employed. Briefly, the
virus permissive cell lines were incubated with the test
medications at different concentrations for 2h, 24h and
48h. The test medication was removed and the cells
were infected with a multiplicity of infection (MOI) of
0.00037 (Flu A), 0.00044 (Para3), 0.00046 RSV, 0.00042
(HRV-14), 0.0004 (HSV-1) and 0.004 (Ad5). The virus
inoculum was removed and subsequently 1) cells were
overlaid with solid medium only ("prophylactic” proto-
col) or 2) cells were overlaid with solid medium contain-
ing the test substances ("therapeutic” protocol) and
cultivated until in the control plaques or CPE appeared.
The percentage of inhibition was calculated in reference
to the untreated control (100% inhibition) and expressed
as relative inhibition (n = 2 in duplicates).
Interferon-a specific ELISA
A commercial IFN-a ELISA (Biosource) was used to
determine the quantity of IFN-a in the cell culture
supernatant. Briefly, cells (96-well round bottom micro-
titer plates, Greiner, Bio-one, Kremsmünster, Austria,
2×1 0
5 cells/well, RPMI 1640, 10% FCS) were seeded
and incubated with the test preparations for the indi-
cated time points. Additional samples were co-stimu-
lated with the appropriate UV-inactivated virus. After
incubation for the indicated time points, the supernatant
was collected and the IFN-a content was quantified
according to the manufacturer instructions. The quan-
tity of IFN-a is proportional to the extinction values at
OD450 nm and is calculated in pg/ml using an IFN-a
standard curve. To calculate an increase or decrease in
percentage terms, the MEM control or co-stimulated
control, respectively, was defined as 100% IFN-a and
thereby served as relative values compared to control.
The data represent the mean values +/- SD (n = 3).
Results
1. Antiviral effect of Gripp-Heel® and Engystol®
As a first step we asked whether Gripp-Heel® and Engys-
tol® reduce infectivity in the prophylactic setting where
cells are only exposed to the medications previously to
infection. The permissive cell lines which are susceptible
only for a certain virus (see below) were thereby pre-
treated for 2 h, 24 h and 48 h with the test preparations,
washed and subsequently infected with the different
viruses (HRV-14, HSV-1, FluA, Para 3, RSV and Ad5).
In the plaque reduction assays and a virus-specific
ELISA (Ad5), Engystol® (ES) and Gripp-Heel® (GH)
induced a slight prophylactic virus inhibition at the low-
est dilution (1:5) when pre-incubated for 48 h against
FluA [ES: 20.7%; GH:15,4], HRV-14 [ES: 25.9%; GH:
18.8%] and HSV-1 [ES:19.6%; GH: 15.9%]). However, a
dose-response relationship was not observed and also
shorter incubation times showed no effect (data not
shown).
In contrast, when the cells were continued to be incu-
bated in the presence of test preparations, we observed
a dose-dependent reduction of infectivity ranging from
20 to 44%, depending on the virus and pre-incubation
time (Fig 1, 2). In particular, Gripp-Heel® and Engystol®
showed dose-dependent antiviral activity against
FluA, HRV-14, HSV-1, Ad5 and Para 3, with Engystol®
(Figure 1a-f, 2a-f) having only a moderate effect on Para
3 (20.7% at dilution 1:5). In contrast, a dose-dependent
inhibition of viral replication of RSV was noted for
Gripp-Heel®, but not for Engystol®. The observed inhibi-
tory effects were influenced by the pre-incubation time
chosen. In the case of FluA, both preparations showed
highest efficacy when pre-incubated for 48 h (ES: 25.7%
and GH: 44.6% at 1:5 dilution). For HSV-1, the best
effects were observed after 24 h of pre-incubation (ES:
30.4%; GH: 30.7% at 1:5 dilutions). For Ad5, the highest
inhibition was observed at 2 h (ES: 30.5%; GH: 31.3% at
1:5 dilution), and for HRV-14, the longer pre-incuba-
tions (24 h and 48 h) showed best efficacy (ES: 39.2%;
GH: 28.6% at 1:5 dilution). Antiviral activity of Gripp-
Heel® against RSV was found only after 2 h pre-incuba-
tion (26.1%); also for Para 3, the best inhibitory effect
was determined after 2 h (29.2%). Through our evalua-
tion of the prophylactic activity, we observed that the
pre-incubation time influences the magnitude of the
antiviral effect in a virus specific manner when the treat-
ment with test preparation was continuous.
2. Effect of Engystol® on type 1 IFN production in virus-
susceptible cell lines
To investigate whether Engystol® can evoke type 1 IFN
production without previous exposure to viral struc-
tures, the effect on virus susceptible cell lines were
tested, which were incubated with the medication in five
dilutions for two days. We observed no significant
increase in IFN (IFN-a ELISA and bioassay) in the
unstimulated cell lines in the presence of Engystol® (data
not shown), indicating that Engystol® could not induce a
spontaneous IFN release in the tested cell lines.
Therefore, we expanded our experimental set-up to
determine whether Engystol® might exert its effect in
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MDCK cell lines were incubated with the corresponding
UV-inactivated virus (described in method section) and
cultivated in the presence of Engystol® (or MEM control,
respectively) for 2 days.
No increase in IFN release was observed for MDCK
cells infected with FluA or Hep-2 cells infected with
HSV-1 (data not shown). However, in HeLa cells
infected with inactivated HRV an increase in IFN pro-
duction was obtained in both assays. A 56%-increase in
IFN release compared to control was observed at a 1:4
dilution of Engystol® in the ELISA assay (Figure 3a).
3. Effect of Engystol® on type I IFN production in PBMCs
In order to determine whether Engystol® modulates the
IFN release in cells of the immune system, human per-
ipheral blood mononuclear cells (PBMCs) were isolated
from 4 healthy donors and incubated for either 2 or 5
d a y sw i t h5d i l u t i o n so fE n g y s t o l ® .I n3o ft h e4d o n o r s ,
a spontaneous, although very small IFN release (< 15 pg/
ml) was noted (data not shown). In contrast, when the
IFN response was primed with UV-inactivated HSV-1
Engystol® elicited a pronounced increase in IFN after
2 days and 5 days of co-cultivation. In the ELISA an up to
4-fold increase in IFN-a production was observed at a
1:4 dilution at day 5 of incubation (Figure 3b). Even higher
dilutions showed a modest dose-response relationship.
These results were confirmed in an independent set
of experiments with 3 additional healthy donors (data
not shown).
4. Effect of Gripp-Heel® on type 1 IFN production
in virus-susceptible cell lines
According to Engystol® the effect of Gripp-Heel® on IFN
release was determined. No significant increase in IFN
was observed in the unstimulated cell lines MDCK,
Hep2 and HeLa in the presence of Gripp-Heel® (data
not shown). Also, Gripp-Heel® did not affect the IFN
Figure 1 Antiviral effect of Engystol® against several viruses. Inhibitory effect of Engystol® on Influenza A (a), Parainfluenza 3 (b), RSV (c),
HRV-14 (d), HSV-1 (e) and Adenovirus 5 (f) were determined using plaque reduction assay and virus-specific ELISA for Ad5, respectively
("therapeutic approach”). Data are shown as percentage of inhibition compared to the untreated control (100% inhibition, n = 4).
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Page 4 of 8Figure 2 Antiviral effect of Gripp-Heel® against several viruses. Inhibitory effect of Gripp Heel® on Influenza A (a), Parainfluenza 3 (b), RSV
(c), HRV-14 (d), HSV-1 (e) and Adenovirus 5 (f) determined using plaque reduction assay and virus-specific ELISA for Ad5, respectively
("therapeutic approach”). Data are shown as percentage of inhibition compared to the untreated control (100% inhibition, n = 4).
Figure 3 In-vitro type 1 IFN production following Engystol® incubation. Effect of Engystol® on type 1 IFN production in HRV-UV infected
HeLa (a) and HSV-UV-co-stimulated PBMCs (b) was determined using IFN-a specific ELISA 5 days after incubation. In figure a data represent
mean values ± SD (N = 3). For the PBMC setting 4 different donors were used for each treatment group (first column = donor 1, second
column = donor 2, third column = donor 3, fourth column = donor 4).
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(HSV-1) cells (data not shown). However, in HeLa cells
treated with inactivated HRV Gripp-Heel® displayed a
modest dose-dependent effect on IFN-a production as
quantified by ELISA (Figure 4a).
5. Effect of Gripp-Heel® on type 1 IFN production in
PBMC
Finally, the effect of Gripp-Heel® on the IFN levels in
stimulated and unstimulated PBMCs was determined. In
a first set of experiments, cells obtained from healthy
donors were incubated with Gripp-Heel® for 4 days.
Blood cells from one (donor 1) of 3 donors exhibited a
small but notable spontaneous release in IFN (data not
shown). In the HSV-primed cells a 4 day incubation
with Gripp-Heel® induced IFN release in all three blood
samples, as quantified by ELISA (Figure 4b). Notably,
the blood from donor 1 showed a pronounced IFN
release even at a higher dilution of Gripp-Heel® (1:32).
This finding was confirmed by similar results from a
second set of experiments (data not shown).
Discussion
This study provides the first results towards understand-
ing how the two ultra-low-dose combination medica-
tions Engystol® and Gripp-Heel® may possibly exert their
antiviral effect, as documented in observational studies
and in a small number of experimental studies [6,7].
Employing virus-permissive cell lines, we confirmed the
inhibitory effect of both medications against a broad
panel of respiratory viruses in vitro (plaque assay) and
provide the first evidences, using two different experi-
mental settings (cell lines and PBMCs) which suggest
that the antiviral effect may be due to the triggered
increase in type 1 IFN production.
Engystol® and Gripp-Heel® are used prophylactically to
ward off viral infections and are valued for their good
tolerability and lack of any known adverse effects [2,5].
The established clinical efficacy, yet not clarified
mechanism of action of the two preparations, formed
the objective of our studies here to investigate the ability
of these medications to reduce infectivity under in vitro
conditions. We found that both preparations had a
modest prophylactic effect against infection with HSV,
FluA and HRV, whilst Engystol® was slightly more effec-
tive than Gripp-Heel® in this case. When the incubation
was continued over the course of the experiment ("ther-
apeutic” setting), however, both medications showed a
pronounced inhibitory activity against all six tested
respiratory viruses except for RSV, which was not inhib-
ited by Engystol®. These findings agree with previously
published data, which demonstrated similar results for
Gripp-Heel® against a broad panel of RNA and DNA
viruses [6].
For Engystol®, the results from the plaque formation
assays, confirm in part previously published results [7].
We did not observe such a strong inhibition (70% to
80%) of Ad5 and HSV, although it should be noted that
these high values were achieved with the highest con-
centration (1:2). As we observed toxicity at a dilution of
1:2 (data not shown), we applied higher dilutions (>1:5).
We could not confirm the reported inhibitory effect
against RSV (37% at dilution 1:2), but did observe an
inhibitory effect against FluA. These different findings
may be due to different multiplicity of infections (MOIs)
employed and dilutions of the test preparation. Despite
our results as well as the previous studies suggest that
the clinical benefits of both preparations may be due to
inhibition of virus infectivity. Oberbaum and colleagues
suggested that Engystol® might have a direct effect on
virus replication, since they did not observe any induc-
tion of IFN-a in an epithelia and embryonic fibroblast
cell line [7]. As discussed below induction of IFN in cell
lines is highly virus- and cell type dependent and might
Figure 4 In-vitro type 1 IFN production following Gripp-Heel® incubation. Effect of Gripp-Heel® on type 1 IFN production in HRV-UV
infected HeLa (a) and HSV-UV-co-stimulated PBMCs (b) was determined using IFN-a specific ELISA 4 days after incubation. In figure a data
represent mean values ± SD (N = 3). For the PBMC setting (b) 4 different donors were used for each treatment group (first column = donor 1,
second column = donor 2, third column = donor 3, fourth column = donor 4).
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showed efficacy against a broad panel of structurally dif-
ferent viruses such as RNA and DNA viruses - envel-
oped and non-enveloped -, it seems likely that Engystol®
and Gripp-Heel® also modulate host defence
mechanisms.
Type 1 IFN production plays an important role in
antiviral response and involves a large family of multi-
functional immuno regulatory proteins. IFN-a/b is
induced by virus infection and cells that respond to IFN
establish an antiviral state. These statements are based
on the observation that IFN-a/b receptor knock out
does not result in an antiviral state and strongly indi-
cates that IFN cytokines are of particular importance for
the immune response to viral pathogens [16]. Induction
of type I interferon can be mediated via various cellular
pathways. The “classical” pathway is characterized by
the phosphorylation of IFN regulatory factors (IRFs)
[17,18]. Furthermore, IFN type I can be induced via
Toll-like receptor (TLR) signalling, modulating the
development of innate and adaptive immune systems
[17,18]. Apparently, the induction of IFN type I mole-
cules results from activation of distinct interacting path-
ways dependent on pathogenic factors and host cell
determinants. We postulate that the observed antiviral
effect of Engystol® and Gripp-Heel® might involve stimu-
lation of IFN.
I nt h ec u r r e n ts t u d yt w oR N Av i r u s e s-F l u Aa n d
H R V-a sw e l la st h eD N Av i r u sH S Vw e r et e s t e do n
susceptible cell lines for their potential to induce type I
IFN production. However, only HRV could induce type
I IFN production in epithelial HeLa cells. In epithelial
cells IRF-3, but not IRF-7, is constitutively expressed
and controls IFN-a/b induction, as described above
[ 1 9 ] .T h e r e f o r e ,I F N a/b gene induction occurs sequen-
tially, wherein the initial IFN-b induction by IRF-3 (first
phase) triggers a positive feedback loop via IRF-7 induc-
tion and IFN-a production, thus amplifying the
response [17]. Adding to the complexity of these pro-
cesses, IFN is induced by cytoplasmic RNA [20,21].
Thus, it may be possible that cytosolic dsRNA, which is
normally produced in the course of virus replication,
would have been required to induce IFN response and
which might account for the failure in IFN production
for FluA and HSV. In the case of HRV, possibly a differ-
ent mechanism might account for the observed IFN
production.
This study shows for the first time using an IFN-a
specific ELISA and a functional bioassay that both medi-
cations increase IFN production in PBMCs, in which
type I IFN production was triggered using UV-inacti-
vated HSV. Inactivated HSV has been previously shown
to induce type I IFN in primary human cells [22,23]. In
particular, IFN-a production can be induced in human
mononuclear cells in the presence of purified, recombi-
nant HSV-1 glycoprotein D [24,25].
With regard to the cell types responsible for the IFN
type I release it is noted, that almost any nucleated cell
in culture, such as macrophages or lymphocytes, can
produce IFNs. However, precursor dendritic cells with
plasmacytoid morphology (pDC) were characterized as a
specialized subset of cells producing the bulk amount of
IFN type one during viral infections [26,27]. It is concei-
vable that pDCs may account for the large part of the
IFN response in isolated PBMCs reported here. Both
Gripp-Heel® and Engystol® triggered an increase in IFN
production only in the presence of viral structures, sug-
gesting that Engystol® and Gripp-Heel® rather exert their
effect when the immune system is already active than
during healthy and inactive immune conditions. We
speculate that this subpopul a t i o nm a yb et h et a r g e tf o r
the IFN release induced by Gripp-Heel® and Engystol®.
However, this needs to be scientifically proven in further
experiments.
IFN-g plays a major immunomodulatory role and is a
key mediator of virus-specific cellular immunity. IFN-a/
b can promote IFN-g expression in T-cells [28] and
a p p e a r st op l a yak e yr o l ei nt h ec o o r d i n a t i o no fi n n a t e
and adaptive immune response during viral infection. In
this respect, a recent report from Engbergs and collea-
gues is noteworthy, as these authors suggest that Engys-
tol® may increase the percentage of IFN-g-producing
lymphocytes in vitro [8]. During the adaptive phase,
IFN-g is mainly produced by activated T-cells, whilst in
the innate phase, natural killer cells are thought to be
the main source of the newly formed IFN-g [18].
Conclusion
In summary, the data presented here provide further
evidence that the two medications, Gripp-Heel® and
Engystol®, have antiviral effect in vitro. Our studies show
f o rt h ef i r s tt i m et h a tE n g y s t o l ®a n dG r i p p - H e e l ®
increase IFN release in HRV-activated HeLa cells and
induce type 1 IFN release in primary immune cells
primed with replication-deficient HSV. We suggest that
these preparations exert their antiviral effect by modu-
lating the type 1 IFN response. Further studies to eluci-
date the signalling pathways involved are warranted in
order to also establish whether pDCs are indeed the
main target cells of these medications. Focusing on den-
dritic cells could be especially useful, as these cells initi-
ate T-cell response and may be the link between the
innate and adaptive immune response.
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